apl. Prof. Dr. Bernd Spriewald

Medizinische Fakultät

Risk Stratification Before Living Donor Kidney Transplantation in Patients With Preformed Donor-specific Antibodies by Different Crossmatch Methods (2024) Ziemann M, Lindemann M, Hallensleben M, Altermann W, Althaus K, Budde K, Einecke G, et al. Journal article Adaptive immune responses are larger and functionally preserved in a hypervaccinated individual (2024) Kocher K, Moosmann C, Drost F, Schülein C, Irrgang P, Steininger P, Zhong J, et al. Journal article Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia (2024) Burmeister T, Ströh AS, Kehden B, Trautmann H, Meyer C, Marschalek R, Larghero P, et al. Journal article, Letter Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL (2024) Stelljes M, Raffel S, Alakel N, Wäsch R, Kondakci M, Scholl S, Rank A, et al. Journal article Adoptive transfer of donor B lymphocytes: a phase 1/2a study for patients after allogeneic stem cell transplantation. (2024) Winkler J, Tittlbach H, Schneider A, Vasova I, Strobel J, Herold S, Maas S, et al. Journal article Definition of a New HLA B*52-Restricted Rev CTL Epitope Targeted by an HIV-1-Infected Controller (2023) El Kenz B, Schmidt K, Ogungbemi-Alt VK, Bergmann S, Steininger P, Korn K, Spriewald B, et al. Journal article Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 study (2023) Gerbitz A, Gary R, Aigner M, Moosmann A, Kremer A, Schmid C, Hirschbuehl K, et al. Journal article Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. (2023) Bergmann C, Müller F, Distler J, Györfi AH, Völkl S, Aigner M, Kretschmann S, et al. Journal article, Letter Outcome of 841 Older Patients (> 55 yrs) with Newly Diagnosed Ph/BCR-ABL Negative ALL Prospectively Treated According to Pediatric-Based, Age-Adapted GMALL Protocols (2022) Goekbuget N, Viardot A, Steffen B, Hahn J, Spriewald B, Martin S, Raffel S, et al. Conference contribution Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (> 55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial) (2022) Stelljes M, Alakel N, Waesch R, Scholl S, Nachtkamp K, Rank A, Haenel M, et al. Conference contribution